Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review

Marie-Caroline Le Bousse-Kerdilès¹,², Marie-Claire Martyré¹,², Michel Samson³

¹ INSERM U602; Hôpital Paul-Brousse; 14 Avenue Paul-Vaillant Couturier, 94807 Villejuif Cedex, France
² Université Paris 11, Institut André Lwoff, 94807 Villejuif Cedex, France
³ EA SeRAIC; INSERM U620; Université de Rennes 1; IFR140, 2 avenue du Pr Léon Bernard, 35043 Rennes Cedex, France

Correspondence: M. Samson, INSERM U620, Université de Rennes 1, 2 avenue du Pr Léon Bernard, 35043 Rennes cedex, France
<michel.samson@univ-rennes1.fr>

Accepted for publication May 30, 2008

ABSTRACT. Chronic fibroproliferative diseases are an important cause of morbidity and mortality in the world. Fibrotic diseases occur in a large variety of vital organs, and the process of fibrosis seems common to all tissues. In all of fibrotic reactions, the underlying cellular and molecular mechanisms involve leukocyte infiltration, the persistence of inflammation in the tissue, and the proliferation of cells with a myofibroblast phenotype. The different cell types participating to this process sustain production of growth factors, proteolytic enzymes, angiogenic factors, and fibrogenic cytokines, which together stimulate the deposition of connective tissue elements that progressively destroy and remodel normal tissue architecture. This review focuses on the comparison of two, major, chronic fibroproliferative diseases: the myelofibrosis which develops in bone marrow, a “fluid” tissue producing circulating haematopoietic cells, and liver fibrosis, which demonstrates all the features of solid tissue damage. We discuss the etiology and histological quantification of each type of fibrosis, the implication of cell partners, cytokines and growth factors, animal models developed to study fibrosis, and antifibrotic therapies for each of these two fibroproliferative disease models.

Keywords: fibroblasts, TGF-beta, extracellular matrix (ECM) components

Fibroproliferative diseases are an important cause of morbidity and mortality with nearly 45% of all deaths in the developed world being attributed to chronic forms of the disease. Indeed, fibrotic diseases occur not only in a large variety of vital organs including lung, liver, kidney, intestine, heart, skin and eye, but also in fluid tissues such as bone marrow (BM), with the loss of organ function leading to death. The diseases include pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kidney disease, macular degeneration and bone marrow fibrosis also called myelofibrosis (MF). Moreover, the fibrotic tissue remodelling that occurs in organs may be involved in the initiation/genesis of cancer, influence cancer metastasis and may accelerate chronic graft rejection in transplant recipients.

In all fibrotic reactions, the underlying cellular and molecular mechanisms involve: leukocyte infiltration, persistence of inflammation in the tissue, and proliferation of cells with a myofibroblast phenotype. These different cell types sustain the production of growth factors, proteolytic enzymes, angiogenic factors and fibrogenic cytokines, which together stimulate the deposition of connective tissue elements that progressively remodel and destroy normal tissue architecture. Thus, the understanding of mechanisms in which cells and a variety of factors are involved is critical for developing treatment strategies for these diseases.

The number of fibroproliferative diseases is large and varied. However, the goal of this review is to compare two types of fibrosis: liver fibrosis, which bears all hallmarks of tissue damage, and myelofibrosis which develops in the bone marrow, a “fluid” tissue generating circulating haematopoietic cells. After a brief definition of both types, this review will focus on the identification of the different or indeed common mechanisms involved in these two diseases. We shall analyse the etiology, histological quantification, involvement of cell partners, cytokines and growth factors, animal models developed to study fibrosis, and antifibrotic therapies for each type.

DEFINITION AND AETIOLOGY

Fibrosis is attributed to excess deposition of extracellular matrix (ECM). This is a complex meshwork comprising various types of collagens, laminin, entactin, heparan sulfate and proteoglycans. It is often defined as a wound-healing response that has gone out of control and that does not lead to normal regeneration following tissue injury. Damage to tissues can result from a variety of acute or chronic stimuli, but pathogenic fibrosis typically results from chronic inflammatory reactions. Many fibrotic disorders have an infectious aetiology, with bacteria, viruses, fungi, and multicellular parasites driving chronic inflammation and the development of fibrosis. Moreover, fibrosis
may also be due to toxic agents such as smoke, chemicals, allergens, or alcohol. Finally, some fibroses arise from autoimmune disease.

Bone marrow fibrosis is a reactive process that can be associated with malignant as well as benign pathologies. It is a complication of several hematological neoplasms such as myeloproliferative disorders, lymphomas and lymphoid leukemias (hairy cell leukaemia, leukaemic transformation of Hodgkin disease), systemic mastocytosis, lymphoid and myeloid acute leukemias, and is also seen in medullar cancer metastasis; in such cases, fibrosis is associated with significant morbidity and mortality. Myelofibrosis has also been described in association with nonmalignant pathologies such as chronic autoimmune diseases e.g. systemic lupus erythematosus, rachitis due to vitamin D deficiency, infectious syndromes or after exposure to toxins or radiation.

During the last few years, a number of studies performed in human and experimental models have improved our knowledge of the complexity of both normal and fibrotic bone marrow stroma, resulting in a better understanding of the development of bone marrow fibrosis. In this review, we will take the example of primary myelofibrosis (PMF), also called myelofibrosis with myeloid metaplasia, a Philadelphia chromosome-negative chronic myeloproliferative disorder (cMPD) that is characterized by the association of myeloproliferation and myelofibrosis [1, 2], to provide an overview of that which is currently known about the cellular and molecular mechanisms of bone marrow fibrosis. In PMF, the stromal reaction that accompanies clonal hematopoietic stem cell proliferation is characterized by a consistent myelofibrosis associated with osteosclerosis (figure 1) and neoangiogenesis. In contrast to the myelofibrosis associated with other MPDs such as chronic myeloid leukemia (CML) or polycythemia vera (PV), fibrosis is present in PMF at diagnosis, although it progresses slowly.

In contrast to bone marrow fibrosis, the causes of liver fibrosis/cirrhosis are better known. Indeed, liver fibrosis/cirrhosis represents the consequences of a sustained wound healing response to chronic liver injury from a variety of causes. The large majority of patients worldwide that have liver fibrosis or cirrhosis has chronic viral hepatitis (due to hepatitis C virus [HCV] or hepatitis B virus [HBV]). The World Health Organization (WHO) estimates that globally about 170 million people are chronically infected with HCV, with 3 to 4 million people being newly infected each year, while 350-400 million people are afflicted with chronic hepatitis B (see: http://www.who.int/en/). The steatohepatitis associated with either alcohol or obesity (non-alcohol steatosic hepatitis (NASH) represents another important cause of liver cirrhosis with an increasing incidence throughout the world. NASH is now estimated by WHO to affect over 50% of the world’s morbidly obese population, involving some 60 million people. However, other etiologies, albeit with smaller numbers of patients, include parasitic diseases (e.g. schistosomiasis), autoimmune attack on

![Figure 1](image-url)

Histological sections of human bone marrow from healthy donors (A) or from patients with myelofibrosis (B, C, D).
hepatocytes or biliary epithelium, neonatal liver disease, metabolic disorders including Wilson’s disease, hemochromatosis and a variety of other storage diseases, chronic inflammatory conditions (e.g. sarcoidosis), drug toxicity (e.g. methotrexate or hypervitaminosis A), and vascular disturbances, either congenital or acquired.

HISTOLOGICAL QUANTIFICATION

Myelofibrosis is defined as an increase in bone marrow fiber content without referring explicitly to the exact quantity or quality (reticulin versus collagen) [3]. In PMF, immunolocalisation studies show a marked neovascularisation [4] in the fibrotic bone marrow stroma together with an increased deposition of types I, III, IV, V and VI collagen, with types I and III being predominant [1, 2] and highly synthesized [5]. An increased deposition of interstitial and basement proteins, fibronectin, laminin, tenascin and vitronectin is also documented in the advanced stages of the disease [6], suggesting that myelofibrosis is a complex process that involves the accumulation and assembly of collagenous ECM components (reticulin) and non-collagenous ECM components (fibronectin). In the past, scoring methods were mainly based on subjective evaluations by individual pathologists using a variety of techniques. Recently, a consensus of European experts has solved this problem by proposing a semi-quantitative grading system regarding the quantity and quality of MF in chronic MPD (cMPD). Four main grades based on assessment of the fiber content and density within hematopoietic cellular areas, have been proposed [7]. These grades discriminate between a scattered, linear, reticulin network with no intersections corresponding to normal BM (MF-0), a loose network of reticulin with many intersections (MF-1), a diffuse and dense increase in reticulin with extensive intersections, occasionally (MF-2), or often (MF-3), associated with focal bundles of collagen.

For the evaluation of fibrosis in liver histology (stage and grade) (figure 2), the most common scoring methods include Metavir [8] and the histological activity index (HAI) also called the Knodell [9]. Briefly, the Metavir scoring system was specially designed for patients with hepatitis C. The scoring consists of a grading and a staging system. The grade gives an indication of the activity or amount of inflammation and the stage represents the amount of fibrosis or scarring. The grade is assigned a number based on the degree of inflammation, which is usually scored from 0-4, with 0 being no activity and 3 or 4 considered as severe activity. The extent of inflammation is important because it is considered a precursor to fibrosis. The fibrosis score is also assigned a number from 0-4: 0 = no scarring, 1 = minimal scarring, 2 = scarring has occurred and extends outside the areas in the liver that contains blood vessels, 3 = bridging fibrosis spreading and connecting to other areas that contain fibrosis, 4 = cirrhosis or advanced

![Figure 2](image-url) 

**Figure 2**

Histological sections of human cirrhotic liver stained with trichrome masson (A) or by red Sirius (B). Histological sections stained with red Sirius of liver from oil-treated mice (C) or from mice treated with an hepatotoxic agent, CCl₄, over 12 weeks (D).
scarring of the liver. The Knodell score or histological activity index (HAI) is also commonly used to stage liver disease. It is a rather more complex process, but some experts believe that it is a better tool for defining the extent of liver inflammation and damage. It is composed of four individually assigned numbers that make up a single score. The first component (peri-portal and/or bridging necrosis) is scored 0-10. The next two components (intralobular degeneration and portal inflammation) are each scored 0-4. The combination of these three markers indicates the amount of inflammation in the liver: 0 = no inflammation, 1-4 = minimal inflammation, 5-8 = mild inflammation, 9-12 = moderate inflammation, 13-18 = marked inflammation.

**CELL PARTNERS**

Two main types of cell partners have to be distinguished in the fibrotic process: cells synthesising fibrogenic growth factors that activate cells producing ECM components.

**Cells synthesising fibrogenic growth factors**

The presence of a variety of immunological abnormalities in PMF first suggested that the lymphocytic lineage could be implicated in the induction and/or maintenance of the disease and favoured the hypothesis of an autoimmune origin. Immune-mediated bone marrow damage was suggested, particularly it was speculated that activation of platelets by circulating immune complexes would result in the release of fibrosis-promoting factors from the platelets and subsequent bone marrow fibrosis [10]. Whereas the pathogenic relevance of these findings has not been elucidated in PMF, the role of lymphocytes, and especially of B lymphocytes as a source of fibrogenic cytokines, has been strongly suggested in hairy cell leukemia [11, 12].

In contrast, a number of findings have led to the concept that the megakaryocytic lineage is pathogenically important in the promotion of myelofibrosis associated with PMF development [13]: i) dysplastic megakaryocyte (Mk) hyperplasia and its close association with the fibrotic tissue, ii) the increased number of circulating megakaryocytes and progenitors, iii) the possible transformation of PMF into acute megakaryoblastic leukaemia. However, the demonstration that megakaryocyte homogenates were able to stimulate the proliferation of bone marrow fibroblasts and the production of collagen has provided the first tangible evidence in support of the role of megakaryocytes and of an Mk-derived growth factor identified as platelet-derived growth factor (PDGF), in the genesis of marrow fibrosis [14]. Further studies have shown that the expression and production of transforming growth factor-beta (TGF-β) were increased in patients’ peripheral blood mononuclear cells identified as megakaryocytic cells at different stages of differentiation/maturation [15]. The report of a steadily increasing percentage of myelofibrosis correlating with the proliferation of Mk in CML underlined the correlation of megakaryocytic cells with fibrosis, and stressed the link between TGF-β and megakaryocytic cells in the pathophysiology of myelofibrosis. Interestingly, megakaryocytes also produce and secrete vascular endothelial growth factor (VEGF), the expression of which can be up-regulated by PDGF, epithelial growth factor (EGF), basic fibroblast growth factor (bFGF) and TGF-β. In PMF, the clustering of Mk close to sinusoids and their intrasinusoidal localization support the concept of interactions between MK and endothelial cells that favour cytokine-mediated bone marrow reactions, including fibrosis and angiogenesis (**figure 3**).

Apart from lymphocytes and megakaryocytes/platelets, monocytes could be alternative sources of fibrogenic growth factors. In PMF, monocytes are activated and over-express IL-1 and TGF-β, suggesting that they may also contribute to the fibrotic process [16, 17]. Whereas contradictory results coming from experimental models of myelofibrosis induced in NOD/SCID mice that are deficient in functional monocytes [18, 19] illustrate that the issue is open, cooperation between MK and monocytes in the production of fibrogenic cytokines remains most likely. With regard to this assumption, it is interesting to note that NF-κB pathway activation is associated with TGF-β production in both cell types [16, 20].

Among the cell partners involved in the liver fibrosis process, the hepatic stellate cells (HSC), also known as Ito cells, which play a central role in fibrosis, synthesize fibrogenic growth factors. However, all neighboring cell types, such as sinusoidal endothelium, Kupffer cells, hepatocytes, platelets and leukocytes, produce cytokines and growth factors that directly or indirectly participate in the initiation and maintenance of the stellate cell phenotype. Activated HSC perpetuate their own activation through several autocrine loops, including the secretion of TGF-β1 and an upregulation of its receptors [21]. The HSC also express keratinocyte growth factor in chronic liver [22]. Endothelial cells are also likely to participate in activation, both by production of cellular fibronectin and via conversion from the latent to active, profibrogenic form. Kupffer cell infiltration and activation also play a prominent role in liver fibrosis. Kupffer cells produce large amounts of cytokines, especially TGF-β1, and can also stimulate matrix synthesis, cell proliferation, and release of retinoids by stellate cells through the actions of both cytokines and reactive oxygen intermediates/lipid peroxides. Proliferation of HSC has been attributed to Kupffer cell-derived TGF-β. TGF-β derived from Kupffer cells markedly stimulates stellate cell ECM synthesis. Platelets are a potent source of growth factors, and are present in the injured liver [23]. Potentially important platelet mediators include PDGF [24] and TGF-β1 (**figure 3**).

**Cells synthesising ECM components**

The key cellular mediator of the myelofibrotic process is the medullar fibroblast, while in liver fibrosis/cirrhosis the key cellular mediator is the HSC, both types of cells being mesenchymal cells. Thus, in bone marrow fibrosis, fibroblasts usually found in close association with collagen fibers, are responsible for reticulin and collagen synthesis [25, 26]. Since no massive increase in fibroblast numbers is observed in the bone marrow of PMF patients, the increased production of reticulin and ECM proteins may rather be due to their activation into myofibroblasts [26] or to an acceleration of their differentiation in matrix-producing cells (collagen-
secreting α-SMA+ fibroblasts) as reported in hairy cell leukaemia [27]. These myofibroblasts are mainly derived from resident mesenchymal cells; however, it has been shown that they can also be derived from epithelial cells in an epithelial-mesenchymal transition process [28, 29]. Recently, circulating fibroblast-like cells, termed fibrocytes, that define a new leukocyte subpopulation derived from bone marrow stem cells and that mediate tissue repair have been identified [30, 31], thus suggesting that cells with different origins, acting together, likely contribute to the collagen production. Interestingly, activated fibroblasts/fibrocytes also produce inflammatory cytokines, growth factors, and chemokines that participate in the persistence of inflammation linked to the fibrotic process.

In liver fibrosis, although several hepatic cell types including the hepatocytes themselves can synthesize ECM proteins (mainly collagen types I and III in the liver parenchyma), HSC are the major source of increased ECM in chronic liver diseases [32-34]. Following liver injury, HSC undergo a phenotypic transformation, with the acquisition of myofibroblast-like features, including increased collagen production and cell contractility. These activated HSC migrate and proliferate at the sites of liver injury, perpetuating hepatic inflammation and playing a pivotal role in the formation of a fibrous scar. Thus, the HSC express virtually all of the key components required for pathological matrix degradation and therefore play a key role not only in matrix production, but also in matrix degradation.
MOLECULAR MECHANISMS OF FIBROSIS

Role of growth factors and cytokines

In PMF, whereas the clonality of the hematopoietic proliferation is well recognised [35], the proliferation of the medullary fibroblasts responsible for the development of the fibrosis is suggested to be polyclonal [36, 37]. Therefore, the stromal reaction appears to be secondary to the production of growth factors including TGF-β, PDGF, β-FGF, VEGF, EGF and platelet factor-4 (PF-4), by hematopoietic cells and especially by dystrophic megakaryocytes from the malignant clone. Interestingly, these cytokines that are powerful regulators of extracellular matrix biosynthesis are also mediators of fibroblast and endothelial cell proliferation, suggesting their involvement in the stromal reaction and reinforcing the hypothesis of a connection between fibrosis and angiogenesis as suggested in various fibrotic diseases including pulmonary and eye fibrosis as well as systemic sclerosis [28].

Historically, PDGF was the first growth factor suggested to participate in PMF bone marrow fibrogenesis through its role in the proliferation/activation of medullary fibroblasts [14, 38]. Several groups have evaluated PDGF activity in myeloproliferative disorders and have reported quantitative changes in platelet PDGF levels. An overall decrease of intraplatelet PDGF levels was observed in the different cMPD with the exception of PMF, where some groups have shown reduced platelet PDGF activity, while others have reported increased PDGF expression [14, 25, 38]. From these studies, it appeared that intraplatelet PDGF levels do not strictly correlate with the degree of fibrosis and that the release of PDGF solely could not account for the complexity of the myelofibrotic process. It seemed likely that additional growth factors were involved, among which TGF-β and bFGF have received particular attention. TGF-β, and especially TGF-β1, is one of the most powerful growth factors in the regulation of the activity of genes involved in the synthesis of the ECM components and of ECM-degrading enzymes [39, 40]. Similarly to its key role in the pathogenic process of tissue fibrosis [41], TGF-β has been also implicated in the development of fibrosis associated with hematological disorders. It has been reported to be highly expressed in hairy cell leukaemia [27] and in acute megakaryoblastic leukemia [11, 42], and to be involved in the pathogenesis of bone marrow reticulin fibrosis observed in these diseases. In PMF, the pathogenic relevance of TGF-β also lies in its capacity to increase the biosynthesis of type I, III and IV collagens, fibronectin, tenasin and proteoglycans and to block matrix degradation by reducing collagenase-like protease synthesis while enhancing protease inhibitor expression. Involvement of TGF-β in the promotion of fibrosis in PMF was first suggested by the demonstration of elevated intraplatelet levels in patients [15, 43]. The increase in TGF-β production by megakaryoblasts in acute megakaryoblastic leukaemia [11, 42], and in TGF-β plasma concentrations in acute megakaryocytic leukaemia [42], further strengthened the hypothesis of a possible contribution of this growth factor to the myelofibrotic process and of megakaryocytes in its production. The normal levels of TGF-β reported in essential thrombocytopenia, an MPD in which the number of MK/platelets is abnormally elevated while myelofibrosis is uncommon, indirectly corroborate this assumption [44]. Finally, the demonstration of a prominent role for TGF-β released from megakaryocytes/platelets in the promotion of myelofibrosis came from studies performed in mouse models of myelofibrosis.

Involvement of additional growth factors, likely acting in conjunction with PDGF and TGF-β must also be considered. Among them, bFGF, is a powerful mitogen for human bone marrow stromal cells and which is a potent angiogenic factor, has been reported to be highly expressed in PMF patients and to participate in the medullar fibrotic reaction [45, 46]. By modulating the function of fibroblasts, IL-1, serum amyloid P substance and calmodulin may also take part in this process; interestingly IL-1β is increased in the serum of PMF patients (personal results) and the calmodulin calcium-binding protein is increased in the urine of MPD patients with fibrosis in contrast to non-fibrotic ones [47]. Finally, the level of VEGF that is particularly involved in angiogenesis, and which also participates in the promotion of fibrosis, has been reported to be higher in the plasma of PMF patients [48]. Actually, by increasing vascular permeability, VEGF enhances the extravasation of plasma proteins into the extravascular space. Such a process might lead to profound alterations in the EMC, which could result in fibrosis.

In liver fibrosis (figure 3), PDGF is the most potent stellate cell mitogen identified [49]. Induction of PDGF receptors early in stellate cell activation increases responsiveness to this potent mitogen, and downstream pathways of PDGF signaling have been carefully characterized in stellate cells. TGF-β is the most potent stimulus for collagen I production by HSC [32-34]. The chemotactic cytokines are involved in the migration of HSC, an action that is characteristic of wound-infiltrating mesenchymal cells in other tissues too. Chemotaxis of stellate cells explains, in part, why HSC align within inflammatory septa in vivo.

The several cytokines, produced by leukocytes, that are recruited to the liver during injury, joining with Kupffer cells, can modulate HSC behaviour and consequently liver fibrosis. The specific role of neutrophils as a stimulus for HSC was demonstrated in a co-culture experiment in which cells activated by fMLP were plated in direct contact with HSC. Activated neutrophils, which are an important source of reactive oxygen species (ROS), increase HSC collagen synthesis 3-fold over control levels via superoxide production [50]. Lymphocytes, including CD4+ T-helper (Th) cells, residing in the liver, represent a further potential source of cytokines and therefore are able to modulate the liver fibrotic process [29]. Th lymphocytes help to orchestrate the host-response via cytokine production and can differentiate into Th1 and Th2 subsets. Thus, Th1 cells produce cytokines that promote cell-mediated immunity, including interferon (IFN)-gamma, tumor necrosis factor (TNF) and IL-2 and have been demonstrated as anti-fibrotic cytokines. In contrast, Th2 cells produce IL-4, IL-5, IL-6 and IL-13, promote humoral immunity, and have been demonstrated as pro-fibrotic cytokines. Th1 cytokines inhibit the development of Th2 cells and Th2 cytokines inhibit the development of Th1 cells; a phenomenon that increases the anti- or pro-fibrotic processes. Further evidence of the importance of Th2 cytokines in liver fibrogenesis has been demonstrated by studies using
mice that lack the Th2 cytokine IL-4 or its receptor IL-4Ra. All these animals show remarkably reduced liver fibrosis.

**Mechanisms of fibrogenic growth factor production**

As regards myelofibrosis, different studies have provided insight into possible mechanisms for the pathological release of fibrogenic growth factors in PMF. Abnormal expression and subcellular distribution of P-selectin, a specific platelet receptor for leucocytes and a component of the α-granule membrane, together with excessive and pathological emperipolesis (i.e. the passage of a cell into the cytoplasm of another cell) of polymorphonuclear leucocytes in Mk, have been observed in bone marrow from patients [51]. Such a phenomenon is reported to result in the progressive destruction of Mk, with degradation and lysis of α-granules and subsequent release of growth factors. Therefore, in PMF, abnormalities in Mk maturation and structure, with conspicuous proliferation and clustering, sublithal cell injury and/or cell lysis, probably account for the elevated fibrogenic growth factor levels detected in patients [46]. Once released, fibrogenic growth factors can be sequestrated in bone marrow stroma by binding to heparan sulfate proteoglycans in extracellular matrix and basement membranes [52, 53]. Their locally raised concentrations, together with their sustained release from abnormal Mk/platelets, would participate in the progressive alteration of bone marrow stroma and the recruitment of fibroblasts into wound sites through interactions with ECM component [54].

In liver fibrosis, TGF-β is produced by Kupffer cells and hepatic stellate cells [55], and its inhibition prevents progression of fibrosis [56]. Convincing proof of the role of Kupffer cells in fibrogenesis was demonstrated when Kupffer cells were suppressed using a mutated form of MCP-1 (CCL2), which functions as a dominant negative mutant. Thus, the blockade of macrophage infiltration inhibits activation of HSC and leads to suppression of liver fibrogenesis [57]. Therefore, while TGF-β1 is required for the attraction of HSC, production of MEC and survival of activated HSC, little is known concerning inducers able to increase the secretion of TGF-β1 by Kupffer cells. In rat, it was shown that TGF-β1 mRNA could not be detected in parenchymal and nonparenchymal cells from normal liver. Nevertheless, human Kupffer cells are an important source of TGF-β1 production even without any stimulation [58, 59]. Thus, large amounts of TGF-β1 were produced by unstimulated Kupffer cells. Among the regulators of TGF-β1 expression, eicosanoids, a fatty acid, could modulate TGF-β production [60]. Octreotide, a somatostatin analog that significantly decreases TGF-β1, has been implicated in the reduction of liver fibrosis [61]. Controversially, works have been reported on the role of LPS in liver fibrosis and in the TGF-β1 expression by Kupffer cells. In vitro, similar to rat KC (CXCL1) in culture, LPS-stimulated human Kupffer cell release TGF-β1 [60]. However, Xidakis et al. [61] have shown that LPS stimulation seems to significantly decrease the TGF-β1 production in primary culture of human Kupffer cells. Recently, the role of LPS and TLR4 has been further elucidated in vivo using TLR4 chimeric mice. In quiescent HSC, TLR4 activation by LPS challenge induces chemotaxis of Kupffer cells, and downregulates the Bambi TGF-β pseudoreceptor to sensitize HSC to TGF-β-induced signals and allow for unrestricted activation by Kupffer cells. Here, the modulation of TGF-β1 signaling by a TLR4-MyD88-NF-kappaB axis is a novel link between proinflammatory and profibrogenic signals [62]. An autocrine or short-loop paracrine effect of TGF-β1 or PDGF has been proposed as a mechanism contributing to the expression of these growth factors by HSC.

**Alteration of the proteolytic environment**

In most cells, TGF-β1 is synthesized as a latent, biologically inactive form that has to be activated to be recognized by its cell-surface receptors in order to trigger biological responses. Mechanisms leading to TGF-β1 activation are complex and not well understood. Although proteolytic processing by plasmin and matrix metalloproteinases (MMP), as well as exposure to ROS may participate in its activation, the conformation change of the latent complex induced by molecular interactions appears to be a prominent mechanism in vivo. Integrins such as αvβ6 and αvβ8 and thrombospondin have been demonstrated to be major activators of TGF-β1 in vivo [63-65]. In PMF, TGF-β1 activation is restricted to the hematopoietic (medullar and spleen) environment and the underlying mechanisms are still unclear. It cannot be ruled out that aberrations in the complex enzymatic machinery that regulates latent TGF-β1 activation may lead to the prolonged release of TGF-β1, thus making the myelofibrotic process even more complex. Therefore, it is most likely that activation of proteolytic enzymes paves the way for the increasing collagen meshwork. Studies investigating plasma from patients with PMF and related Philadelphia chromosome-negative cMPD for aberrant MMP and tissue inhibitors of metalloproteinase (TIMP) protein levels, have suggested that elevated TIMP together with decreased MMP levels might be essential for fibrosis formation [66, 67]. Interestingly, the increased levels of MMP-14, a key pericellular collagenolyis in pathological vascular remodeling and angiogenesis, observed in progressive myelofibrosis shed new light on a potentially important candidate in the PMF stromal reaction, including fibrosis and angiogenesis [6]. It is most likely that the role of other molecules, including members of the urokinase-type plasminogen activator system, elastases and stromelysins, concomitantly interacting in the process of ECM remodeling, complicates the network of aberrant proteolytic mechanisms in PMF [5]. The JAK/STAT pathway has been reported to be involved in the activation of genes responsible for metalloproteinase synthesis. Interestingly, a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F) has been discovered in half of PMF patients [68-71]. However, whereas this JAK2 mutation is suggested to be responsible for the altered haematopoiesis in the mutated patients, it does not modify the matrix-modeling gene expression that is predominantly related to the stage of disease [5]. In liver, quantitative and qualitative changes in matrix protease activity also play an important role in the ECM remodeling accompanying fibrotic injury. HSC express almost all of the key components required for pathological matrix degradation, and therefore play a key role not only in matrix production, but also in matrix degradation. A
growth of matrix-metalloproteinases has been identified that are calcium-dependent enzymes, which specifically degrade collagen and noncollagenous substrates [72, 73]. These enzymes include: interstitial collagenases (MMP-1, MMP-8 and MMP-13); gelatinases (MMP-2 and MMP-9); stromelysins (MMP-3, MMP-7, MMP-10 and MMP-11); membrane-type (MMP-14, MMP-15, MMP-16, MMP-17, MMP-24 and MMP-25); and a metalloelastase (MMP-12). Inactive metalloproteinases can be activated through proteolytic cleavage by either membrane-type matrix metalloproteinase 1 (MT1-MMP) or plasmin, and inhibited by binding to specific inhibitors known as tissue inhibitors of metalloproteinases (TIMP). Thus, net collagenase activity reflects the relative amounts of activated metalloproteinases and their inhibitors, especially TIMP. HSC are an important source of MMP-2, as well as increases in the specific MMP inhibitor molecules, TIMP-1 and TIMP-2, leading to a net decrease in protease activity, and therefore, more matrix accumulation.

EXPERIMENTAL MODELS

To date, there are several experimental models of myelofibrosis in mouse. One of the first models described, induced by the myeloproliferative sarcoma virus (MPSV), shares many clinical and biological characteristics with PMF, and especially a massive fibrosis observed not only in the bone marrow, but also in the spleen and the liver of infected mice [74, 75]. Very interestingly, in this model, the role of growth factors and cytokines produced by stromal cells in the genesis of fibrosis closely mimics that observed in the human disease. More recently, two other murine models have been reported: one is induced by administration of suprapharmacological doses of thrombopoietin (TPO), a physiological regulator of megakaryocytopoiesis (TPO<sup>high</sup> mice) [76, 77]; the other is observed in mice harbouring a decreased expression of the GATA1 megakaryocytic transcription factor (GATA-1<sup>low</sup> mice) [78]. In these models, the development of fibrosis is associated with increased numbers of Mk cells and high levels of TGF-β [79]. However, the most significant demonstration of the central role of TGF-β in the myelofibrotic process comes from studies in which mice were grafted with either bone marrow stem cells from homozygous TGF-β-null (TGF-β<sup>-/-</sup>) or wild-type (WT) littermates infected with a retrovirus encoding the murine TPO protein. In this model, myelofibrosis occurred only in mice repopulated with WT cells with no reticulin deposition was seen in animal reconstituted with TGF-β<sup>-/-</sup> cells [80]. Finally, most recently, mouse models of MPD associated with myelofibrosis, in which the JAK2-V617F mutation was overexpressed by retroviral transduction [81, 82] or by transgenesis [83, 84], have been described.

Several animal models have been developed to study liver fibrosis (figure 2). Challenges of mice with carbon tetrachloride (CCl<sub>4</sub>), a hepatotoxic molecule that generates a trichloromethyl-free radical, leading to an oxidative stress-mediated lipid peroxidation and membrane damage, results in the development of liver fibrosis. In the same way, injection of parasites, such as <i>Schistosoma mansoni</i> causes granulomas around schistosome eggs and, liver fibrosis. Bile duct ligation (BDL) is also used in mouse to induce liver fibrosis which mimicks human chronic cholestatic liver disease. Finally, the use of transgenic (conventional or “knockout”) mice has allowed the study of liver fibrosis against different genetic background. Thus, the impact of TGF-β1 on liver fibrosis has been well documented in a TGF-β1-knockout mouse model [85], in the remarkable attenuation of the development of liver fibrosis by using soluble type II TGF-β receptor [86], and in adenoviral delivery of dominant-negative TGF-β receptor [87]. More recently, the role of Th1 or Th2 cytokines has been assessed in liver fibrosis induced by repeated CCl<sub>4</sub> administration or schistosoma infection [29]. Thus, the use of severe, combined, immunodeficiency (SCID) mice for T-cell depletion, the C57/BL6 mice for Th1 predominance and BALB/c mice for Th2 predominance shows that the degree of fibrosis is modified significantly in immunocompetent mice from both strains. Immunocompetent C57/BL6 mice, whose lymphocyte cytokine profile includes IFN-gamma, actually exhibit less fibrosis than SCID mice from the same background. When C57/BL6 mice, with targeted disruption of IFN-gamma, are treated with CCl<sub>4</sub>, fibrosis returns to the level seen in C57/BL6 SCID mice. However, immunocompetent BALB/c mice, whose lymphocyte cytokine profile includes the fibrogenic compounds IL-4 and TGF-β, exhibit more fibrosis than BALB/c SCID mice. Among all of the studies examining immunoregulation of fibrosis, those demonstrating modulation by T lymphocytes appear the most convincing. Furthermore, the relevance of the Th2 cytokines, IL-4 and IL-13 in liver fibrosis, has been investigated in mice infected with <i>Schistosoma mansoni</i>. Thus, treatment with neutralizing mAb against IL-4 has allowed evaluation of the role of this cytokine in the generation of parasite egg-induced, cell-mediated responses and hepatic pathology. Animals treated with anti-IL-4 before egg deposition showed decreased IL-4, IL-5, and IL-10 production, and anti-IL-4-treated, infected mice showed consistent and marked reductions in hepatic collagen deposition [88]. In the same way, use of IL-13 inhibitor allows the development of hepatic fibrosis to be blocked [89, 90]. IL-4-deficient, IL-13-deficient, and IL-4/13-deficient mice, when infected by <i>Schistosoma mansoni</i>, presented a reduction in hepatic fibrosis, compared to wild type mice [91, 92].

CLINICAL IMPACT AND THERAPEUTIC CHALLENGE

Despite the substantial progress made over the past few years, there are currently no approved treatments that directly and effectively target the complex mechanism(s) of fibrosis. This raises the issue of the existence of common mechanisms that regulate fibrosis in the various fibroproliferative diseases. The extreme complexity of the cellular network involved in ECM secretion and in fibrogenic growth factor production can explain why targeting only one cell type is not sufficient for the effective treatment of fibrosis. Whereas the long and chronic evolution of fibrosis is difficult to reproduce in mice, the use of the experimental models of myelofibrosis has been very helpful for testing the efficacy of new therapeutic strategies such as adenoviral-mediated TGF-β1 inhibition [93] or proteasome inhibitor bortezomib [94] targeting either the cytokine (TGF-β) distribution or production related to NF-kB.
activation, respectively. However, whereas these strategies are promising in mouse models, preliminary data from therapeutic trials have not demonstrated the efficiency of such inhibitors in reducing fibrosis, suggesting that removing the endogenous agent is not sufficient to treat a multifactorial disease such as this. Therefore, other therapeutic strategies, including molecules targeting cytokine-mediated signalling, are currently being explored [95], their rational lying in the recent discovery of the JAK2 mutation in MPD that constitutively activates the JAK2 pathway [2]. Whereas preliminary data show significant clinical activity of such inhibitors in MPD patients including those with PMF, their effect on fibrosis has not yet been reported. Thus, until now, alloegenic haematopoietic cell transplantation offers the only therapy available for patients with PMF that has the potential to reverse bone marrow fibrosis between six and 12 months after transplantation [96]. Interestingly, the efficiency of bone marrow cell transplantation in reducing fibrosis is not restricted to bone marrow fibrosis, as it has been recently proposed as a potential treatment for liver fibrosis in mice [97, 98].

As TGF-β plays a major role in liver fibrosis, several therapeutic strategies have been developed to target this molecule in vivo [99, 100]. Anti-TGF-β approaches were established and successfully utilized for the treatment of experimental fibrogenesis in animals. Dominant negative TGF-β receptors (TβaR), generated by fusing the Fc domain of human IgG and the N-terminal (extracellular) fragment of TβaRII (Fc:TβaRII) were applied to suppress fibrosis. Further, the over-expression of Smad7, a transcriptional factor involved in intracellular TGF-β signalling, achieved efficient inhibition of liver fibrosis. Likewise, soluble TGF-β receptor II expression reduced experimental fibrogenesis in vitro and in vivo, partially by decreasing intracellular ROS and inhibiting NADH oxidase. Similar approaches, aimed at reducing endogenous IL-13 or suppressing IL-13 receptor signalling, have been developed. Thus, IL-13 immunoneutralization reduces liver fibrosis in mice [89, 90]. In conclusion, several approaches that specifically target pro-fibrogenic TGF-β signalling are effective at reducing liver fibrosis in mice and therefore show promise for the treatment of liver disease in humans. However, to ensure patient safety approaches with strong specificity need to be established.

CONCLUSION

Whereas bone marrow and liver fibrosis occur in different organs, analysis of their pathophysiological mechanisms reveals a number of similarities including: a predominant implication of TGF-β, and a key role of fibroblasts as both a cellular target of TGF-β and a central cell for the production of ECM components. Furthermore, in both types of fibrosis, the chronic inflammatory response seems to be required for induction of the fibrotic process. In contrast, the etiology and the nature of the cells producing the fibrogenic factors are different. However, the complexity and the specificity of the cellular and humoral network participating in these fibrotic processes, as well as their long and chronic evolution, account for the current lack of effective antifibrotic therapies, challenging both research-ers and the pharmaceutical industry to intensify and gather their efforts.

Acknowledgments. We thank the Ministère de la Recherche et de l’Enseignement Supérieur and the INSERM for their support. The authors also thank Dr Bruno Turlin (Service d’anatomo-pathologie, CHU de Rennes, Rennes) for helpful cooperation.

REFERENCES


57. Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppres-
sion of macrophage infiltration inhibits activation of hepatic stel-
late cells and liver fibrogenesis in rats. *Gastroenterology* 2005;
58. Hata J, Ikeda E, Uno H, Asano S. Expression of hepatocyte growth
factor mRNA in rat liver cirrhosis induced by N-nitrosodimethyl-
amine as evidenced by in situ RT-PCR. *J His-
tochem Cytochem* 2002; 50: 1461.
59. Luckey SW, Petersen DR. Activation of Kupffer cells during the
course of carbon tetrachloride-induced liver injury and fibrosis in
60. Roland CR, Goss JA, Mangino MJ, Hafenerrichter D, Flye MW.
Autoregulation by eicosanoids of human Kupffer cell secretory
products. A study of interleukin-1, interleukin-6, tumor necrosis
factor-alpha, transforming growth factor-beta, and nitric oxide.
61. Kidakis C, Ljumovic D, Manousou P, Notas G, Valatas V, Ko-
lios K, Kouroumalis E. Production of pro- and anti-fibrotic agents
by rat Kupffer cells; the effect of octreotide. *Dig Dis Sci* 2005;
50: 935.
62. Seki E, De Minicis S, Oesterreicher CH, Kluwe J, Osawa Y, Bren-
er DA, Schwabe RF. TLRL4 enhances TGF-beta signaling and
63. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM,
Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a
64. Yang Z, Mu Z, Dabovic B, Jurukovski V, Yu D, Sang J, Xiong X,
Munger JS. Absence of integrin-mediated TGFbeta1 activation in
vivo recapitulates the phenotype of TGFbeta1-null mice. *J Cell
65. Munger JS, Huang X, Kawakatsu H, *et al.*. The integrin alpha v
beta 6 binds and activates latent TGF beta 1: a mechanism for
regulating pulmonary inflammatory and fibrosis. *Cell* 1999; 96:
319.
66. Wang JC, Novotsky A, Chen C, Novotsky AD. Plasma matrix met-
alloproteinase and tissue inhibitor of metalloproteinase in patients
with agnogenic myeloid metaplasia or idiopathic primary myelofi-
67. Wang JC. Importance of plasma matrix metalloproteinases (MMP)
and tissue inhibitors of metalloproteinase (TIMP) in development
of fibrosis in agnogenic myeloid metaplasia. *Leuk Lymphoma*
68. James C, Ugo V, Le Couedic JP, *et al.* A unique clonal JAK2 muta-
tion leading to constitutive signalling causes polycythaemia vera.
tyrosine kinase JAK2 in human myeloproliferative disorders.
mutation of JAK2 in myeloproliferative disorders. *N Engl J Med*
2005; 352: 1779.
tyrosine kinase JAK2 in polycythemia vera, essential thombo-
cytocemia, and myeloid metaplasia with myelofibrosis. *Blood*
2002; 100: 3495.
73. Benyon RC, Arthur MJ. Extracellular matrix degradation and the
74. Le Bousse-Kerdiles MC, Smadja-Joffe F, Klein B, Caillou B, Jas-
min C. Study of a virus-induced myeloproliferative syndrome asso-
75. Le Bousse-Kerdiles MC, Souyri M, Smadja-Joffe F, Praloran V,
Jasmin C, Zehner H. Enhanced hematopoietic growth factor pro-
duction in an experimental myeloproliferative syndrome. *Blood*
production by hematopoietic cells induces a fatal myeloprolifera-
77. Van XQ, Lacey D, Hill D, Shen Y, Fletcher F, Hawley RG, Mc-
Niece IK. A model of myelofibrosis and osteosclerosis in mice
induced by overexpressing thrombopoietin ( mpl ligand): reversal
78. Vannucchi AM, Bianchi L, Cellai C, *et al.* Development of myel-
ofibrosis in mice genetically impaired for GATA-1 expression
79. Vannucchi AM, Bianchi L, Paoloiti F, *et al.* A pathobiological path-
way linking thrombopoietin, GATA-1, and TGF-beta1 in the devel-
80. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W,
Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-
81. Werner G, Mercher T, Okabe R, Levine RL, Lee BH, Gillililan-
d DG. Expression of JAK2V617F causes a polycythaemia vera-like
disease with associated myelofibrosis in a murine bone marrow
82. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W,
Villeval JL, JAK2V617F expression in murine hematopoietic cells
leads to MPD mimicking human PV with secondary myelofibrosis.
83. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Drnhofer S,
Schwaller J, Skoda RC. Ratio of mutant JAK2-V617F to wild-type
JAK2 determines the MPD phenotypes in transgenic mice. *Blood*
2008; 111: 3931.
84. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Bren-
er DA. The role of TGFbeta1 in initiating hepatic stellate cell
85. Xing S, Wanting TH, Zhao W, *et al.* Transgenic expression of
JAK2V617F causes myeloproliferative disorders in mice. *Blood*
2008; 111: 5109-17.
86. George J, Roulot D, Koteliansky VE, Bissel DM. In vivo inhibi-
tion of rat stellate cell activation by soluble transforming growth
factor beta type II receptor: a potential new therapy for hepatic
87. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of
increasing egg-induced hepatic fibrosis.
88. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An
activating mutation in the JAK2 tyrosine kinase JAK2 in human
89. Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD,
Schwaller J, Skoda RC. Ratio of mutant JAK2-V617F to wild-type
JAK2 determines the MPD phenotypes in transgenic mice. *Blood*
2008; 111: 3931.
90. Xing S, Wanting TH, Zhao W, *et al.* Transgenic expression of
JAK2V617F causes myeloproliferative disorders in mice. *Blood*
2008; 111: 5109-17.
91. George J, Roulot D, Koteliansky VE, Bissel DM. In vivo inhibi-
tion of rat stellate cell activation by soluble transforming growth
factor beta type II receptor: a potential new therapy for hepatic
92. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of
increasing egg-induced hepatic fibrosis.


